These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 35752279)
1. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study. Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279 [TBL] [Abstract][Full Text] [Related]
2. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558 [TBL] [Abstract][Full Text] [Related]
3. Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study. Santomasi C; Buonamico E; Dragonieri S; Iannuzzi L; Portacci A; Quaranta N; Carpagnano GE Acta Biomed; 2023 Feb; 94(1):e2023028. PubMed ID: 36786266 [TBL] [Abstract][Full Text] [Related]
4. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399 [TBL] [Abstract][Full Text] [Related]
5. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. Tversky J; Lane AP; Azar A Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845 [TBL] [Abstract][Full Text] [Related]
6. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients. Domínguez-Sosa MS; Cabrera-Ramírez MS; Marrero-Ramos MDC; Dávila-Quintana D; Cabrera-López C; González Cuervo H; Benítez Del Rosario JJ; Carrillo-Díaz T Ann Med; 2024 Dec; 56(1):2411018. PubMed ID: 39364704 [TBL] [Abstract][Full Text] [Related]
8. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps. Matsuno O; Minamoto S Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667 [TBL] [Abstract][Full Text] [Related]
9. [Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma]. Boiko NV; Lodochkina OE; Kit MM; Kuleshova VG; Nedashkovskaya NG Vestn Otorinolaringol; 2021; 86(2):43-48. PubMed ID: 33929151 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial. Emson C; Han JK; Hopkins C; Asimus S; Cann JA; Chain D; Wu Y; Reddy Y; McCrae C; Cohen D; Kreindler JL; Werkström V; Jison M; Wagenmann M; Bachert C Br J Clin Pharmacol; 2024 Aug; 90(8):1952-1963. PubMed ID: 38715387 [TBL] [Abstract][Full Text] [Related]
12. Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study. Canonica GW; Consani L; Malerba L; Pelaia G; Vultaggio A; Immunotherapy; 2024; 16(14-15):913-923. PubMed ID: 39287158 [TBL] [Abstract][Full Text] [Related]
13. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma. Paçacı Çetin G; Arslan B; Yılmaz İ J Asthma; 2024 Jan; 61(1):20-26. PubMed ID: 37437223 [TBL] [Abstract][Full Text] [Related]
14. Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience. Santus P; Saad M; Casartelli A; Lorusso R; Milani L; Danzo F; Busatto P; Radovanovic D Ann Med; 2024 Dec; 56(1):2407523. PubMed ID: 39373532 [TBL] [Abstract][Full Text] [Related]
15. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP. Guo CL; Liu FF; Wang DY; Liu Z Curr Allergy Asthma Rep; 2023 Dec; 23(12):703-713. PubMed ID: 37987873 [TBL] [Abstract][Full Text] [Related]
16. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps. Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C Front Immunol; 2023; 14():1121237. PubMed ID: 37063895 [TBL] [Abstract][Full Text] [Related]
17. The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma. De Corso E; D'Amato M; Carpagnano GE; Pelaia G; Bonini M Curr Allergy Asthma Rep; 2023 May; 23(5):237-248. PubMed ID: 36995525 [TBL] [Abstract][Full Text] [Related]
18. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229 [TBL] [Abstract][Full Text] [Related]
19. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease]. Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588 [No Abstract] [Full Text] [Related]